Leslie Meltzer
Chief Tech/Sci/R&D Officer bij ORCHARD THERAPEUTICS PLC
Profiel
Leslie Meltzer is currently the Chief Medical Officer at Orchard Therapeutics Plc.
Prior to this role, Dr. Meltzer served as the Vice President-Medical Affairs at Keryx Biopharmaceuticals, Inc. from 2016 to 2018.
Dr. Meltzer holds a doctorate degree from Stanford University School of Medicine.
Actieve functies van Leslie Meltzer
| Bedrijven | Functie | Begin |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01-06-2018 |
Eerdere bekende functies van Leslie Meltzer
| Bedrijven | Functie | Einde |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 01-06-2018 |
Opleiding van Leslie Meltzer
| Stanford University School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
